Emergent Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EMERGENT, and when can generic versions of EMERGENT drugs launch?
EMERGENT has three approved drugs.
There are seven US patents protecting EMERGENT drugs.
There are seventy-three patent family members on EMERGENT drugs in nineteen countries and one supplementary protection certificate in one country.
Summary for Emergent
| International Patents: | 73 |
| US Patents: | 7 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 3 |
Drugs and US Patents for Emergent
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emergent Biodefense | TEMBEXA | brincidofovir | TABLET;ORAL | 214461-001 | Jun 4, 2021 | RX | Yes | Yes | 8,962,829 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Emergent Biodefense | TEMBEXA | brincidofovir | TABLET;ORAL | 214461-001 | Jun 4, 2021 | RX | Yes | Yes | 10,487,061 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Emergent Biodefense | TEMBEXA | brincidofovir | SUSPENSION;ORAL | 214460-001 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Emergent Biodefense | TEMBEXA | brincidofovir | TABLET;ORAL | 214461-001 | Jun 4, 2021 | RX | Yes | Yes | 9,303,051 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Emergent | NARCAN | naloxone hydrochloride | SPRAY, METERED;NASAL | 208411-002 | Jan 24, 2017 | DISCN | Yes | No | 9,707,226 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for EMERGENT drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 4 mg/spray | ➤ Subscribe | 2016-07-15 |
International Patents for Emergent Drugs
Supplementary Protection Certificates for Emergent Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1685839 | 92292 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
